Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Symptoms and General Pathology

Musculoskeletal Diseases

Blood and Lymph Conditions

Rare Diseases

Lung Neoplasms

Adenocarcinoma

Neoplasm Metastasis

Adenocarcinoma of Lung

Bone Neoplasms

Bone Marrow Diseases

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Carcinoma

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Neoplastic Processes

Bone Diseases

Hematologic Diseases

Lung Adenocarcinoma

Patients entering the group have a suspected first bone metastasis of adenocarcinoma lung cancer and should undergo bone biopsy to histologically prove the diagnosis.

The vast majority of bone biopsy are performed under CT-scan. In some rare cases, the histology will be performed during surgery (either biopsy of the bone metastasis or surgical piece when treating a fracture).

Bone metastases biopsy

Cyrille Confavreux, MD, PhD

Nadège Trehet-Mendel

Mortality due to non small cell lung cancers is the first cause of cancer death in men around the world. Lung adenocarcinoma regularly induces bone metastases responsible for high morbidity and impaired life quality. Overall survival of these patients is poor. Thus the investigators aimed to identify if some bone and metabolic parameters were associated with overall survival.

Patients and Methods POUMOS is a prospective cohort of patients suffering from adenocarcinoma lung cancers with a first bone metastasis (stage IV). All patients have a bone biopsy with molecular status characterization of the tumor for EGFR, KRAS, BRAF and ALK. Bone metastasis localizations are obtained by bone scintigraphy or FDG-PET/CT. Whole body composition is obtained by DEXA scan (Hologic®). The investigators assessed also fasting blood levels of bone and metabolic biomarkers.

Survival analyses will be performed using a proportional hazard regression model.

Urine Serum and plasma Bone biopsy Whole blood

Association of Bone and Metabolic Parameters With Overall Survival in Patients With Bone Metastases From Adenocarcinoma Lung Cancer (POUMOS)

Whole body densitometry is performed at baseline

Molecular characterization of the bone metastases by PCR (EGFR, KRAS, BRAF) and FISH (ALK)

Hospices Civils de Lyon

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Association of Bone and Metabolic Parameters With Overall Survival in Patients With Bone Metastases From Adenocarcinoma Lung Cancer (POUMOS)	NCT02810262	Bone Metastases Lung Cancer	Bone metastases...	18 Years -	Hospices Civils de Lyon
Association of Bone and Metabolic Parameters With Overall Survival in Patients With Bone Metastases From Adenocarcinoma Lung Cancer (POUMOS)	NCT02810262	Bone Metastases Lung Cancer	Bone metastases...	18 Years -	Hospices Civils de Lyon

Spots Global Cancer Trial Database for bone biomarkers